Table 2.
Mean blood pressure in age-matched controls and STZ-induced diabetics during stimulation with SIN-1 and ACh
| Blood pressure at 1–2 weeks (mmHg) | Blood pressure at 8–10 weeks (mmHg) | Blood pressure at 18–20 weeks (mmHg) | ||||
|---|---|---|---|---|---|---|
| Experimental protocol | Control (n = 6) | Diabetic (n = 6) | Control (n = 6) | Diabetic (n = 8) | Control (n = 8) | Diabetic (n = 6) |
| Ringer solution | ||||||
| SIN-1 | 116.8 ± 5.0 | 111.9 ± 10.4 | 95.5 ± 8.3 | 108.8 ± 6.4 | 109.2 ± 6.7 | 114.2 ± 4.4 |
| ACh | 115.3 ± 5.3 | 109.7 ± 9.9 | 94.8 ± 7.8 | 109.1 ± 6.0 | 108.7 ± 5.0 | 115.8 ± 2.1 |
| l-NNA +indomethacin | ||||||
| SIN-1 | 114.4 ± 4.7 | 113.8 ± 8.8 | 96.4 ± 7.2 | 110.5 ± 6.4 | 102.0 ± 7.6 | 117.9 ± 4.0 |
| ACh | 113.6 ± 4.6 | 117.9 ± 9.5 | 95.8 ± 5.6 | 110.5 ± 7.2 | 100.9 ± 7.5 | 121.5 ± 3.7* |
| TEA + l-NNA +indomethacin | ||||||
| SIN-1 | 115.9 ± 5.1 | 120.4 ± 9.1 | 98.9 ± 6.0 | 118.5 ± 6.4* | 105.6 ± 6.9 | 122.0 ± 4.1 |
| ACh | 113.5 ± 4.3 | 116.7 ± 12.1 | 94.4 ± 5.1 | 110.9 ± 8.4 | 103.9 ± 8.3 | 121.9 ± 2.7 |
| Time-averaged blood pressure levels | ||||||
| 115.2 ± 0.6 | 115.2 ± 1.1 | 96.4 ± 0.6‡‡ | 111.5 ± 1.0** | 105.3 ± 0.9†‡ | 118.9 ± 1.1†** | |
Mean arterial blood pressure values in age-matched controls and STZ-induced diabetics were significantly different only twice throughout the experimental procedure, once in the 8–10 week group in the presence of TEA + L-NNA + indomethacin during stimulation with SIN-1, and once in the 18–20 week group in the presence of l-NNA + indomethacin during stimulation with ACh. Blood pressure levels, i.e.series of blood pressure values determined throughout the experimental procedure, are given here averaged over time. Among STZ-induced diabetics, mean blood pressure levels were not different between the 1–2 week and the 8–10 or the 18–20 week groups. Among age-matched controls, blood pressure levels varied significntly between all age groups. Data are given as means ± s.e.m.
P < 0.05
P >10−7 compared to age-matched controls.
P >10−4
P >10−13 compared to same treatment group at 1–2 weeks.
P < 0.005 compared to same treatment group at 8–10 weeks.